Discovery and validation of new antitubercular compounds as potential drug leads and probes

Tuberculosis

Volumn 89, Issue 5, 2009, Pages 331-333

  Goldman, Robert C ^a   Laughon, Barbara E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chemical probes; Drug development; High throughput screening; Mycobacteria; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CELL GROWTH; DRUG INDUSTRY; HEALTH CARE DELIVERY; HIGH THROUGHPUT SCREENING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR LIBRARY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 70350764818     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2009.07.007     Document Type: Note

References (19)

1. Cho S.H., Warit S., Wan B., Hwang C.H., Pauli G.F., and Franzblau S.G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51 (2007) 1380-1385
2. Franzblau S.G., Witzig R.S., McLaughlin J.C., Torres P., Madico G., Hernandez A., et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36 (1998) 362-366
3. Gruppo V., Johnson C.M., Marietta K.S., Scherman H., Zink E.E., Crick D.C., et al. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 50 (2006) 1245-1250
4. Lenaerts A.J., Degroote M.A., and Orme I.M. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 16 (2008) 48-54
5. Lenaerts A.J., Gruppo V., Brooks J.V., and Orme I.M. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47 (2003) 783-785
6. Woolhiser L., Tamayo M.H., Wang B., Gruppo V., Belisle J.T., Lenaerts A.J., et al. In vivo adaptation of the Wayne model of latent tuberculosis. Infect Immun 75 (2007) 2621-2625
7. Woolhiser L.K., Hoff D.R., Marietta K.S., Orme I.M., and Lenaerts A.J. Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice. Antimicrob Agents Chemother 53 (2009) 306-308
8. Cohen T., Colijn C., Finklea B., Wright A., Zignol M., Pym A., et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS One 3 (2008) e2363
9. Pillay M., and Sturm A.W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 45 (2007) 1409-1414
10. Mlambo C.K., Warren R.M., Poswa X., Victor T.C., Duse A.G., and Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 12 (2008) 99-104
11. Goldman R.C., Laughon B.E., Reynolds R.C., Secrist III J.A., Maddry J.A., Guie M.A., et al. Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility. Infect Disord Drug Targets 7 (2007) 92-104
12. White E.L., Southworth K., Ross L., Cooley S., Gill R.B., Sosa M.I., et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen 12 (2007) 100-105
13. Lenaerts A.J., Bitting C., Woolhiser L., Gruppo V., Marietta K.S., Johnson C.M., et al. Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 52 (2008) 1513-1515
14. Vicente E., Villar R., Burguete A., Solano B., Perez-Silanes S., Aldana I., et al. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob Agents Chemother 52 (2008) 3321-3326
15. Villar R., Vicente E., Solano B., Perez-Silanes S., Aldana I., Maddry J.A., et al. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 62 (2008) 547-554
16. Ananthan S., Faaleolea E.R., Goldman R.C., Hobrath J.V., Kwong C.A., Laughon B.E., et al. High throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 89 (2009) 334-353
17. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CA, Maddox C, et al. A molecular libraries screening center network antituberculosis assay. Tuberculosis; 2009, doi:10.1016/j.tube.2009.07.006.
18. Alland D., Steyn A.J., Weisbrod T., Aldrich K., and Jacobs Jr. W.R. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 182 (2000) 1802-1811
19. Weber W., Schoenmakers R., Keller B., Gitzinger M., Grau T., oud-El B.M., et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc Natl Acad Sci U S A 105 (2008) 9994-9998